Drugs / 68Ga-NODAGA-RGD
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02666547 | Mar 2014 → Aug 2023 | — | University of Lausanne Hospitals | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01608516 | Apr 2012 → Jul 2026 | atherosclerosis, carotid artery disorder | University of Lausanne Hospitals | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NODAGA-RGD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02666547 ↗ |
| Modality | Diagnostic / imaging agent | “for imaging αvβ3 integrins involved in tumor angiogenesis” PMID 32382869 ↗ May 2020 |
| Route | Intravenous | “200 MBq 68 Ga-NODAGA-RGD will be administered i.v.” NCT01608516 ↗ |